Prof. Jun Guo (郭军)
MD, PhD — Vice President, Peking University Cancer Hospital & Institute
ASCO 2026 Milestone: Prof. Guo is the principal investigator of the MIZAR-003 Phase II randomized trial (LBA 9509), which reported a 42% ORR, 4.3-month median PFS (HR 0.43, p=0.0002), and zero treatment-related deaths in a population where 81.8% of patients had acral or mucosal melanoma. Full results →
Clinical Trial Leadership
Prof. Jun Guo is the principal investigator for the MIZAR-003 GC101 TIL therapy Phase II pivotal trial in advanced melanoma — one of the largest randomized TIL therapy studies reported to date, enrolling 98 patients with predominantly acral and mucosal subtypes.
Professional Affiliations
- Vice President, Chinese Society of Clinical Oncology (CSCO)
- Chairman, CSCO Melanoma Expert Committee
- Vice President (Asia), Melanoma World Society (MWS)
- Director, Department of Melanoma and Sarcoma, PKU Cancer Hospital
- Deputy Director, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education
Career & Milestones
ASCO 2026 LBA — MIZAR-003 Phase II Results
Presented first results of GC101 TIL therapy in advanced melanoma (LBA 9509). The study met its primary endpoint with 42% ORR, 4.3 mo PFS (HR 0.43, p=0.0002), and zero treatment-related deaths — the largest randomized TIL therapy dataset reported in melanoma.
MIZAR-003 Phase II Trial Initiation
Launched the randomized Phase II trial of GC101 TIL therapy vs investigator's choice chemotherapy in advanced melanoma patients who progressed on anti-PD-1 therapy, enrolling acral, mucosal, and cutaneous subtypes.
Role at Peking University Cancer Hospital
As Vice President of PKU Cancer Hospital and head of the Melanoma and Sarcoma Department, Prof. Guo leads the largest and most authoritative melanoma treatment center in Asia.
Research Focus
Prof. Guo's research has focused on improving outcomes for Chinese melanoma patients — a population where acral and mucosal subtypes predominate. His work bridges the gap between Western melanoma research and the distinct clinical reality of Asian patients, where tumor biology, treatment response patterns, and drug access differ substantially from Western populations.
Key insight: Under Prof. Guo's leadership, Peking University Cancer Hospital has treated the largest cohort of melanoma patients in Asia, generating critical real-world data on acral and mucosal melanoma treatment outcomes that are underrepresented in global clinical trials.
External Resources
Frequently Asked Questions About Prof. Jun Guo
Who is Prof. Jun Guo?
Prof. Jun Guo (郭军) is Vice President of Peking University Cancer Hospital and a world-renowned melanoma and sarcoma oncologist. He serves as Vice President of CSCO, Chairman of the CSCO Melanoma Expert Committee, and Vice President (Asia) of the Melanoma World Society (MWS).
What is Prof. Guo's role in the GC101 melanoma trial?
Prof. Guo is the lead Principal Investigator of MIZAR-003, the landmark Phase II randomized controlled trial of GC101 TIL therapy in advanced melanoma. The results — 42% ORR, HR 0.43, zero treatment-related deaths — were presented as a Late-Breaking Abstract at ASCO 2026.
What are Prof. Guo's professional affiliations?
Prof. Guo holds leadership positions including: Vice President, CSCO; Chairman, CSCO Melanoma Expert Committee; Vice President (Asia), Melanoma World Society; Chairman, Beijing Cancer Prevention and Treatment Society; and Fellow of the European Academy of Sciences.
How can I be treated by Prof. Guo?
Patients interested in the GC101 melanoma trial can contact CancerPath at clinicaltrials@juncell.com for an eligibility assessment. Prof. Guo leads the trial at Peking University Cancer Hospital in Beijing.
Learn About GC101 for Melanoma
Read the full ASCO 2026 results and understand how TIL therapy may be an option for advanced melanoma patients.
Melanoma Treatment Overview →